ARTICLE | Management Tracks
Arcus’ Grossman to join Gilead as SVP of oncology clinical research
Plus: Nuyten joining Nektar and updates from Janux, UKI2S, Arena and ArsenalBio
July 20, 2021 1:54 AM UTC
Bill Grossman will leave Arcus Biosciences Inc. (NYSE:RCUS) as CMO to become SVP of oncology clinical research at Gilead Sciences Inc. (NASDAQ:GILD), where he will oversee the alliance to co-develop and co-commercialize Arcus’ cancer portfolio. Kartik Krishnan, SVP of clinical development at Arcus Biosciences Inc., will assume complete leadership of clinical development, effective on July 26.
Nektar Therapeutics (NASDAQ:NKTR) hired Dimitry Nuyten as SVP and CMO. Nuyten, who was most recently CMO at Aduro Biotech Inc., previously held oncology development leadership roles at Pfizer Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY). ...